Coloma Jason V 4

4 · Maze Therapeutics, Inc. · Filed Jun 24, 2026

AI-generated summary of this filing

Updated Jun 24, 2026

Maze Therapeutics CEO Jason Coloma Sells 27,858 Shares

What Happened

Jason V. Coloma, CEO of Maze Therapeutics (MAZE), reported open-market sales totaling 27,858 shares for aggregate proceeds of roughly $725,495. The filings show: 1,953 shares sold on 2026-06-22 at $26.00 ($50,781); 2,040 shares sold on 2026-06-22 at $26.00 ($53,040); and 23,865 shares sold on 2026-06-23 at a reported weighted-average price of $26.05 ($621,674). These were sales (not purchases).

Key Details

Transaction dates and prices:
- 2026-06-22: 1,953 shares @ $26.00 = $50,781
- 2026-06-22: 2,040 shares @ $26.00 = $53,040
- 2026-06-23: 23,865 shares @ reported weighted avg $26.05 = $621,674
Total proceeds: approximately $725,495.
Reporting/filing: Form 4 filed 2026-06-24; transactions occurred 2026-06-22 and 06-23 — appears to be within the standard two-business-day Form 4 filing window.
Footnotes of note:
- F1: Sales were effected under a Rule 10b5-1 trading plan adopted Feb 6, 2026 (pre-arranged trading plan).
- F2 / F5: Reported prices are weighted averages; the filing notes sales occurred across multiple transactions at per-share price ranges (e.g., $26.00–$26.025 and $26.00–$26.185) and the filer can provide a breakdown on request.
- F3 / F4: Some securities are held directly by the Coloma Family Trust and The Coloma 2021 Irrevocable Trust, for which Mr. Coloma and his spouse serve as co-trustees.
Shares owned after the transactions: not specified in the provided excerpt of the filing.

Context

The sales were made under a pre-established 10b5-1 plan, which generally allows insiders to sell pre-scheduled amounts regardless of any subsequent material nonpublic information. Sales under such plans are common and do not necessarily indicate a change in the insider's view of the company.
As these are disposals (S), they are less informative than purchases about insider sentiment; retail investors may note the size and timing but should not infer motive from the sale alone.

Form 4

Period: 2026-06-22

DirectorChief Executive Officer

Transactions

Sale
Common Stock
[F1][F2][F3]
2026-06-22$26.00/sh−1,953$50,781→ 342,944 total(indirect: By Trust)
Sale
Common Stock
[F1][F4]
2026-06-22$26.00/sh−2,040$53,040→ 25,930 total(indirect: By Trust)
Sale
Common Stock
[F1][F5][F3]
2026-06-23$26.05/sh−23,865$621,674→ 319,079 total(indirect: By Trust)

Footnotes (5)

[F1]This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026.
[F2]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.00 to $26.025 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 5 of this Form 4.
[F3]These securities are directly held by the Coloma Family Trust (the "Family Trust"), for which the reporting person and his spouse serve as co-trustees.
[F4]These securities are directly held by The Coloma 2021 Irrevocable Trust (the "Irrevocable Trust"), for which the reporting person and his spouse serve as co-trustees.
[F5]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.00 to $26.185 per share, inclusive.

Signature

/s/ Courtney Phillips, as attorney-in-fact|2026-06-24

1 file